-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Myr-101 in Canavan Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Myr-101 in Canavan DiseaseDrug Details:Myr-101 is under development for the treatment of typical Canavan disease. It...
-
Product Insights
Aspabruk CHP Plant
Aspabruk CHP Plant is a 25.2MW biopower power project located in Narke, Sweden. The project is currently active. The project started its commercial operations in 1973. The project is owned by Ahlstrom-Munksjo Aspa Bruk AB. Aspabruk CHP Plant profile includes core details such as plant name, technology, capacity, status, plant proponents (owners, developers etc.), owner stakes etc as well as key operational data including generation, year online, decommissioning year, capital expenditure etc. Details on project specific contacts along with relevant...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – rAAV-Olig001-ASPA
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry rAAV-Olig001-ASPA Drug Details rAAV-Olig001-ASPAÂ is under development for the treatment of typical Canavan disease. It...
-
Product Insights
Canavan Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Canavan Disease is a gene-linked neurological disorder in which the brain degenerates into spongy tissue riddled with microscopic fluid-filled spaces. Cause includes a mutation in the gene which directs the production of the enzyme aspartoacylase (ASPA) allows the build-up of N-acetylaspartic acid (NAA) in the brain. The build-up of NAA causes damage to myelin. Symptoms include lack of motor development, feeding difficulties, abnormal muscle tone, an abnormally large, poorly controlled head, paralysis, blindness, or hearing loss. The Canavan Disease pipeline...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BBP-812
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry BBP-812 Drug Details BBP-812 is under development for the treatment of Canavan disease. It...
-
Product Insights
Aspartoacylase (Aminoacylase 2 or ACY2 or ASPA or EC 3.5.1.15) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Aspartoacylase (Aminoacylase 2 or ACY2 or ASPA or EC 3.5.1.15) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Aspartoacylase (Aminoacylase 2 or ACY2 or ASPA or EC 3.5.1.15) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics,...
-
Sector Analysis
Outlook for Viral Vector Contract Manufacturing – Gene Therapies, Cell Therapies, and COVID-19 Vaccines
The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain COVID-19 vaccines that require a viral vector, notably those from AstraZeneca and Johnson & Johnson (J&J). This report reveals that viral vector production is limited by insufficient manufacturing capacity, an inefficient manufacturing process, and the requirement for complex specialist facilities. There are 14 therapies/vaccines that use a viral vector (gene therapies, gene-modified cell therapies, and...